Acta Med. 2021, 64: 183-186

https://doi.org/10.14712/18059694.2021.31

Guillan-Barré Syndrome after First Vaccination Dose against COVID-19: Case Report

Daniel Čenščáka, Leoš Ungermannb, Ivana Štětkářovác, Edvard Ehlerd,*

aDepartment of Neurology, District Hospital Pardubice, Czech Republic
bDepartment of Radiology, Faculty of Health-Care study, Pardubice University, District Hospital Pardubice, Czech Republic
cDepartment of Neurology, 3rd Medical Faculty Charles University, Prague, and University Hospital Královské Vinohrady, Prague, Czech Republic
dDepartment of Neurology, Faculty of Health-Care Study, Pardubice University, District Hospital Pardubice, Czech Republic

Received April 5, 2021
Accepted August 10, 2021

References

1. Hampton LM, Aggarwal R, Evans SJW, Las B. General determination of causation between Covid-19 vaccines and possible adverse events. Vaccine 2021; 39: 1478–80. <https://doi.org/10.1016/j.vaccine.2021.01.057> <PubMed>
2. Abu-Rumeileh S, Abdelhak A, Foschi M, Tuman H, Otto M. Guillain-Barré syndrom spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021; 268(4): 1133–70. <https://doi.org/10.1007/s00415-020-10124-x> <PubMed>
3. Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus 2021; 13(2): e13426.
4. Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association. IDCases 2021; 24: e01143. <https://doi.org/10.1016/j.idcr.2021.e01143> <PubMed>
5. Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021; 14(4), e242956. <https://doi.org/10.1136/bcr-2021-242956> <PubMed>
6. Márquez Loza AM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain- Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial: Temporal Associations Do Not Imply Causality. Neurology 2021: 10.1212/WNL.0000000000011881.
7. Merkies I. Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies. Muscle Nerve 2000; 23: 1393–401. <https://doi.org/10.1002/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O>
8. Dufour C, Co TM, Liu A. GM1 ganglioside antibody and COVD-19 related Guillain Barre Syndrome: A case report, systemic review and implication for vaccine development. Brain Behav Immun Health 2021; 12: 100203. <https://doi.org/10.1016/j.bbih.2021.100203> <PubMed>
9. Park YS, Lee KJ, Kim SW, Kim KM, Su BC. Clinical features of post-vaccination Guillain-Barré Syndrom in Korea. J Korean Med Sci 2017; 32: 1154–9. <https://doi.org/10.3346/jkms.2017.32.7.1154> <PubMed>
10. Soni R, Heindl SE, Wiltshire DA, Vahora IS, Khan S. Antigenic variability a potential factor in assessing the relationship between Guillain Barré syndrome and influenza vaccine – up to date literature review. Cureus 2020; 12(9): e10208.
11. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmune Rev 2021; 20(4): 102792. <https://doi.org/10.1016/j.autrev.2021.102792> <PubMed>
12. Kochkar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance. Vaccine 2020; 38(40): 6194–8. <https://doi.org/10.1016/j.vaccine.2020.07.013> <PubMed>
13. Lunn MP, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations. Brain 2021; 144(2): 357–60. <https://doi.org/10.1093/brain/awaa444> <PubMed>
14. Li X, Ostropolets A, Makadia R, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. Preprint. medRxiv 2021; 2021.03.25.21254315.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive